Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews (original) (raw)

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial

Clive Kelly, Anita Patel

BMJ (Clinical research ed.), 2015

View PDFchevron_right

Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice

Markku J Kauppi

Rheumatology, 2017

View PDFchevron_right

The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference

Rosario Foti

Rheumatology (Oxford, England), 2018

View PDFchevron_right

Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT

Christopher McCabe

Health technology assessment (Winchester, England), 2018

View PDFchevron_right

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

Taylor Blachley

Annals of the Rheumatic Diseases, 2020

View PDFchevron_right

Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trials

Joachim Listing

Arthritis & Rheumatism, 2006

View PDFchevron_right

Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis

Hasan Yazici

Clinical and experimental rheumatology

View PDFchevron_right

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis

Zsombor Zrubka

Advances in Therapy, 2019

View PDFchevron_right

Cost-effectiveness of combination disease-modifying antirheumatics vs. tumour necrosis factor inhibitors in active rheumatoid arthritis: TACIT trial

Fowzia Ibrahim

Arthritis Care & Research

View PDFchevron_right

Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists

Lesley-Ann Miller

Joint Bone Spine, 2006

View PDFchevron_right

The impact of escalating conventional therapy in rheumatoid arthritis patients referred for anti-tumour necrosis factor-alpha therapy

Paul Emery

Rheumatology (Oxford, England), 2004

View PDFchevron_right

Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis

Ana Rodrigues

Rheumatology, 2012

View PDFchevron_right

Cost Utility of Tumour Necrosis Factor-α Inhibitors for Rheumatoid Arthritis

Rashid Kazerooni, Anthony Morreale

PharmacoEconomics, 2012

View PDFchevron_right

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

Alberto Alonso

BMC Musculoskeletal Disorders, 2008

View PDFchevron_right

Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis

Alfons Den Broeder

Annals of the Rheumatic Diseases, 2003

View PDFchevron_right

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

Sae Ochi

Arthritis Research & Therapy

View PDFchevron_right

Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry

Joel Kremer

Annals of the rheumatic diseases, 2014

View PDFchevron_right

The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug

Catherine Reynolds

BMC musculoskeletal disorders, 2014

View PDFchevron_right

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Olalekan Uthman

Health Technol Assess, 2011

View PDFchevron_right

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

Ted Mikuls

Current rheumatology reports, 2003

View PDFchevron_right

Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland

Markku J Kauppi

Scandinavian Journal of Rheumatology, 2016

View PDFchevron_right

Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?

md mainuddin

Modern Rheumatology

View PDFchevron_right

Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up

Ahmed Fathy

International Journal of Rheumatic Diseases, 2012

View PDFchevron_right

Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor

Maria Sole Chimenti

Journal of International Medical Research, 2016

View PDFchevron_right

Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology

Gavin Lee

Clinical Rheumatology, 2011

View PDFchevron_right

Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder

Ronan Mullan

Arthritis Research & Therapy, 2013

View PDFchevron_right

anti-TNF agent? (TNF) agents after previous failure of an versus alternative anti-tumour necrosis factor arthritis benefits from switching to rituximab Which subgroup of patients with rheumatoid

Anca I Ciurea

2010

View PDFchevron_right

Impact of Stopping Tumor Necrosis Factor-inhibitors on Rheumatoid Arthritis Patients' Burden of Disease

LINA WIDYA

Arthritis care & research, 2017

View PDFchevron_right

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Delphine Courvoisier, Axel Finckh

Annals of the Rheumatic Diseases, 2010

View PDFchevron_right

Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders?

Fowzia Ibrahim

Rheumatology

View PDFchevron_right

Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database

Rachelle Buchbinder

Rheumatology, 2011

View PDFchevron_right

Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis

Mariangela Manfredi, Maurizio Benucci

International journal of immunopathology and pharmacology

View PDFchevron_right